

## In this Winter 2019 issue:

- ❖ System Activity Update
- ❖ User Tips
  - National Patient Search
  - Requesting multiple dose types during and after initial authorisation
- ❖ Ig Governance Update

## System Activity Update

As of 22 July there were:

- 13,834 patients with active authorisations, and
- 13,469 registered users accessing BloodSTAR as Authorisers, Medical Officers (Prescribers), Nurses, Admin Support and Facility Administrators.


In June 2019, there were 1,004 initial authorisation requests and 17,366 dispense episodes of IVIg/SCIg in BloodSTAR nationally.

## User Tips

### National Patient Search

BloodSTAR allows the roles of Medical Officers (Prescribers), Nurses, Admin Support and Authorisers to view a patient's record at another facility and/or state. This may be required for travelling patients or those transferred from another facility.

1. Click the 'Patient' tab and select 'Search' from the dropdown.
2. Enter in the patient's authorisation number or at least two search terms (given name and family name are deemed as one search term).



The screenshot shows the 'Patient Search' form in the BloodSTAR system. It includes fields for 'Authorisation Number', 'FAMILY NAME' (with 'SMITH' entered), 'Given Name' (with 'Sally' entered), 'MRN/URN/Patient ID', and 'Date of Birth' (with '01-Jan-2001' entered). There are also dropdown menus for 'Search Scope' (set to 'National') and 'Reason' (set to 'Patient has presented for treatment'). A green 'Search' button and a 'Clear' button are at the bottom of the form. Below the form, a search results table is displayed for the criteria: FAMILY NAME: SMITH, Given Name: Sally, Date of Birth: 01-Jan-2001. The table has columns for FAMILY NAME, Given Name, MRN/URN/Patient ID, Date of Birth, IHI, and a 'View' link. One result is shown: SMITH, Sally, NBA Test Facility, 01-Jan-2001, with a 'View' link. At the bottom, there are pagination controls showing '1' of 1 items and '10 items per page'.

FAMILY NAME	Given Name	MRN/URN/Patient ID	Date of Birth	IHI	
SMITH	Sally	NBA Test Facility	01-Jan-2001		<a href="#">View</a>

3. Select the search scope (state or national), and a reason from the dropdown, then click 'Search'.
4. This will bring up the patient's record which can be accessed by clicking on the 'View' link beside their name.

## Requesting multiple dose types during and after initial authorisation

When requesting an initial authorisation in BloodSTAR, certain medical conditions allow the Medical Officer (Prescriber) to request more than one dose type at a time, such as a loading dose and a maintenance dose. When filling in the dose section of the authorisation request, the system will automatically display all doses available for request by the Prescriber.

Step 3

Patient Weight \*  kg

Patient Height  cm

☐ Use Ideal Body Weight Adjusted Dosing ⓘ  
Ideal body weight adjusted dosing is not recommended in patients who are: aged less than 18 years; less than 152cm in height; or pregnant. Where the Dose Determining Weight is greater than the patient's actual weight, use the patient's actual weight to calculate the Ig dose.

☒ Loading Dose  
One loading dose of 0.4 g/kg in the first month of therapy (in addition to the maintenance dose) is permitted if the serum IgG level is <4 g/L.

☐ Dissemination Enterovirus Dose  
One dose of 2 g/kg at any stage is permitted (in addition to the maintenance dose) in the management of disseminated enterovirus infection.

☐ Maintenance Dose  
0.4 g/kg every four weeks or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range. More frequent dosing to achieve IgG trough level of up to 9 g/L is permitted if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. A total dose of up to 1 g/kg may be given over any four week period.

If the medical condition allows the Medical Officer (Prescriber) to request multiple dose types (e.g. a loading dose, maintenance dose and disseminated enterovirus dose) in the initial authorisation but only one is requested, the other dose types can still be requested after the initial request is approved. These other doses will be available to be requested under the current authorisation section of a patient's record, as shown below.

Authorisation **XT84989G**

Authorisation Number [Q XT84989G](#)

Authorisation Date 10-Apr-2019

Medical Condition Acquired-hypogammaglobulinaemia — haematological malignancy or post HSCT

Specific Condition Memory B cell deficiency secondary to haemopoietic stem cell transplantation (HSCT)

Indication Prevention of recurrent bacterial infections due to hypogammaglobulinemia associated with haematological malignancies or post haemopoietic stem cell transplant

Treating Specialist Immunology at NBA BloodSTAR Test - NBA Test Facility

Regimen

Dose Type	Dose	Infusion Method	Action
Loading Dose	PRIVIGEN 10% - 30.00 grams once only.	Intravenous	<a href="#">+ Request Change</a>
<a href="#">+ Request Additional Maintenance Dose</a>			
<a href="#">+ Request Additional Disseminated Enterovirus dose</a>			

Authorisation End Date 02-Oct-2019 Continuing supply is conditional on a review being conducted prior to this date.

Treating Facility NBA Test Facility

Administering Facility NBA Test Facility

Dispensing Facility Z BloodNet Test Facility

[View Treatment Plan](#)

[Edit](#) [+ Record Review](#)

## Ig Governance Update

### National Policy: Access to Government Funded Immunoglobulin Products in Australia (National Policy)

The National Policy sets out the process that must be followed, and describes the rules and requirements that must be complied with, to access government-funded Ig products in Australia.

The National Policy has been revised with effect from 15 July 2019. The update takes into account feedback from stakeholders, clarifies policy objectives and provides additional information to further support the latest release of BloodSTAR and Version 3 of the Criteria. The update does not change arrangements for access to government-funded Ig products.


The latest edition of the National Policy is available [here](#) and replaces all previous editions.

---

### Access to SCIg for CIDP

From 1 August 2019, subcutaneous immunoglobulin (SCIg) will be available for chronic inflammatory demyelinating polyneuropathy (CIDP) under the national blood arrangements.

This arrangement will be in place pending the outcome of a current Health Technology Assessment (HTA) review evaluating the use of immunoglobulin in the treatment of CIDP. The outcomes of the HTA review will inform more permanent arrangements. Further information about the HTA review is available at <https://www.blood.gov.au/health-technology-assessment-reviews-immunoglobulin>.



### For further information

Further information on BloodSTAR is available online at [www.blood.gov.au/bloodstar](http://www.blood.gov.au/bloodstar).

We welcome feedback and suggestions on how we can improve this newsletter. If you have any topics

you would like included in future newsletters, please let us know by calling 13 000 BLOOD (13 000 25663) or by sending an email to [support@blood.gov.au](mailto:support@blood.gov.au)